AVITA Medical has expanded its management team in commercial, legal and medical affairs functions to support the planed US launch of its RECELL Autologous Cell Harvesting Device in the treatment of burns.
Joining AVITA Medical are General Counsel Donna Shiroma; Terry Bromley, commercial operations vice president; and Debbie Garner, global marketing vice president. The Company also announced that Katie Bush, has been promoted to medical affairs vice president.
As General Counsel, Shiroma is responsible for all legal operations of AVITA. With over 20 years of legal and compliance experience in the pharmaceutical and medical device industries, she has played an instrumental role in transitioning companies from clinical to commercial entities.
Prior to joining AVITA Medical, Shiroma served in roles of increasing responsibility as corporate counsel, general counsel, vice president of legal, chief privacy and compliance officer, and chief commercial officer for Ascend Therapeutics, PDL BioPharma, and several Johnson & Johnson companies.
Bromley, Vice President, Commercial Operations, has broad commercial responsibility for the planned U.S. launch of the RECELL device including management of the Commercial Field Team, Sales Training, Sales Operations and Customer Service. Bromley led sales and marketing operations for a number of medical products, including wound healing and skin care, with Crawford Healthcare, Emergent BioSolutions, Convatech and Bristol-Myers Squibb.
As global marketing, vice president, Garner is responsible for leading the long-term commercial plan for AVITA Medical, focusing initially on the RECELL Device. Garner joins AVITA Medical from Allergan, where she served as medical dermatology franchise executive marketing director. While at Allergan she also led global pipeline and business development for aesthetic and therapeutic dermatology products including BOTOX Cosmetic and Juvederm. Previously, Ms. Garner held various marketing roles at Takeda Abbott Pharmaceuticals (TAP).
As a result of her promotion to Vice President, Medical Affairs, Dr. Katie Bush has responsibility for the development and implementation of educational programs, medical-scientific communications, and supporting company-sponsored scientific research and clinical studies. Dr. Bush will also oversee AVITA’s Medical Science Liaison and Medical Education teams. Through her career Dr. Bush has contributed to the development and commercialization of products for soft tissue regenerative applications, including multiple product lines focused on skin regeneration. She holds a doctorate in Biomedical Engineering & Medical Physics from The University of Massachusetts & Worcester Polytechnic Institute, Worcester, MA, completing a thesis on the development of a novel collagen-based skin substitute to enhance re-epithelialization.
CEO Michael Perry said: “These leaders and their respective teams join AVITA Medical at an exciting time as we take the steps to prepare for a successful launch of the RECELL Device in the US.
“We are pleased to have such a strong group of professionals join us and look forward to benefiting from their experience in the commercialization of products in the regenerative medicine and skin care space.”
The RECELL Device is an investigational medical device in the U.S. that is designed to enable medical professionals to produce, at the point-of-care, a REGENERATIVE EPIDERMAL SUSPENSION (RES) using a small sample of the patient’s own skin.
The autologous suspension contains cells necessary to regenerate epidermis and provides a new way to achieve permanent closure in burns and other wounds while reducing the amount of skin harvested at the time of surgery. Reduction in donor-site skin requirements has important benefits from both clinical and health economic perspectives.
A US Premarket Approval (PMA) application for the treatment of burn injuries is currently under review by the US Food and Drug Administration (FDA). The Company expects completion of the FDA review of the PMA during the third quarter of calendar 2018, followed by US approval and market launch.
In April 2018 researchers from major burn centers throughout the US made six presentations of data describing the clinical and cost-savings advantages of the RECELL Device in the treatment of severe burns at the 50th Annual Meeting of the American Burn Association (ABA), in Chicago.
Source: Company Press Release